TickerTalks
Browse all tickers →
TickerTalks›$BMY
BMBMY

Bristol-Myers Squibb Company

Strong FundamentalsStrong FundamentalsRevenue growing 3% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (151/wk), no spike
$BMY·$132B·Drug Manufacturers - General·Healthcare
$66.58-0.6%YTD+23.8%1Y+42.0%
Mentions · last 7 days
2026-08-20: 19 posts2026-08-21: 24 posts2026-08-22: 7 posts2026-08-23: 15 posts2026-08-24: 12 posts151+5%
Price updated 2d ago·X counts updated 6d ago
BMBMY
$BMYBristol-Myers Squibb Company
$66.58-0.55%151 posts+5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BMY, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-08-30

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Camzyos data + Opdivo LOE runway — a compressed pharma name at a cheap multiple.

Bristol-Myers Squibb is a large-cap pharma with a maturing oncology franchise (Opdivo) and a next-generation product engine (Camzyos, plus cell-therapy and CAR-T investments). Shares are +24% YTD and +42% TTM at $67.

  • Revenue and EPS are stable at scale: quarterly revenue ran $12.27B / $12.22B / $12.50B / $11.49B with gross margin at 69%, quarterly EPS at $0.64 / $1.08 / $0.53 / $1.31 — analysts model $48.4B and $6.61 EPS for the full year, so at $67 the stock is at roughly 10x forward, cheap for a big-pharma name with a real pipeline.
  • Camzyos (mavacamten) five-year data is the durable pillar: BMS presented up to five years reinforcing the long-term efficacy and safety of Camzyos in symptomatic obstructive HCM — that's the kind of longitudinal readout that expands prescriber confidence and per-patient duration, both critical to the revenue trajectory.
  • The counter is real and dated: BMS pulled a $380M Cellares CAR-T manufacturing deal, and Opdivo has 587 days to LOE with IPF data pending — those are the two specific concerns that keep BMY from going straight up, and both need to be addressed on the Oct 29 print.

An Oct 29 print that shows Camzyos revenue accelerating and any post-Opdivo LOE bridge (Opdualag, growth-story specifics) extends the coil into a real breakout; a mavacamten commercial deceleration or an IPF Opdivo miss is what invalidates the setup.

What to watch: The Oct 29 Q3 print — Camzyos revenue growth, Opdivo LOE bridge commentary, and any strategic-partnership updates. A mavacamten commercial deceleration or Opdivo IPF miss is what invalidates the setup.

On the calendar: 2026-10-29 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment⚠7 posts analyzed · as of 2026-08-29 · top-engagement diverged

Bristol-Myers chatter is mixed. On the positive side, a shareholder lawsuit trial got a firm November 8, 2027 date after rehearing denied, and mavacamten franchise commentary around ACACIA-HCM is neutral-to-positive. Bears cite BMS pulling a $380M Cellares CAR-T manufacturing deal, 587 days to Opdivo LOE with IPF data pending, and mention BMY as potential AZN acquisition target. Directional tone is muddled.

Read the AI verdict + X sentiment for $BMY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large pharma with key oncology (Revlimid, Opdivo) and cardiovascular drugs, managing significant patent-cliff headwinds.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $BMY.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $BMY

Neutral — Large pharma with key oncology (Revlimid, Opdivo) and cardiovascular drugs, managing significant patent-cliff headwinds; limited read-through from drug manufacturers - general macro dynamics to this specific revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+47.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
16.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
25.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
10.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
39.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
68.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$2.04$1.60+27.5%
Q1 2026Apr 30, 2026$1.58$1.42+11.3%
Q4 2025Feb 5, 2026$1.26$1.23+2.4%
Q3 2025Oct 30, 2025$1.63$1.52+7.2%
Next earningsThu, Oct 29·consensus EPS $1.68

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$11.5B+2.6%70.2%28.5%$1.31$757.0M
Q4 FY25$12.5B+1.3%67.2%11.4%$0.53$1.6B
Q3 FY25$12.2B+2.8%71.9%29.8%$1.08$6.0B
Q2 FY25$12.3B+0.6%65.8%33.6%$0.64$3.6B

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$48.4B$48.2B – $48.9B$6.61$6.52 – $6.7716
FY27$47.1B$46.1B – $48.4B$6.34$5.69 – $7.0919
FY28$41.3B$38.3B – $45.6B$5.49$4.11 – $6.6321
FY29$37.8B$36.7B – $39.4B$4.91$4.72 – $5.1910
FY30$37.0B$35.9B – $38.7B$4.84$4.65 – $5.1110

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.92%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.235-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 25Phil M HolzerSVP and Controller500 sh$34KSellApr 1David V ElkinsCFO30.0K sh$1.9M
+ 35 other (16 awards · 9 exempts · 7 inkinds · 3 others) in window

See when $BMY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJul 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

BMY (BMY) reported financial results for second quarter of 2026 via 8-K Item 2.02, filed 2026-07-30. Full financials are in the attached press release (Exhibit 99.1). Quarterly earnings contain headline P&L, balance sheet, and guidance. Investors should review the exhibit for revenue, margins, EPS, and any updates to full-year outlook.

8-KShareholder voteMay 88-K — Item 5.07: Shareholder vote
AI summary

Bristol-Myers Squibb (BMY) held its 2026 Annual Meeting of Shareholders on May 5, 2026, at which all 11 director nominees were elected. Additional proposals voted on at the meeting are described in the filing. BMY is a large-cap biopharmaceutical company with a broad portfolio of oncology, cardiovascular, and immunology drugs.

8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Bristol-Myers Squibb (BMY) reported Q1 2026 financial results on April 30, 2026. Items 2.02 and 7.01 cover the earnings press release and investor webcast disclosure under Regulation FD, respectively. BMY is a major biopharmaceutical company with key products including Revlimid (loss-of-exclusivity), Eliquis, Opdivo, and Camzyos.

+ 14 other (3 13Gs · 3 11-Ks · 3 proxys · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the Europeangurufocus.com·1d agoBristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026businesswire.com·1d agoOpinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investorsfool.com·1d ago232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLCdefenseworld.net·1d agoBank OZK Invests $474,000 in Bristol Myers Squibb Company $BMYdefenseworld.net·2d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$PFE$NVO$JNJ$GILD$ABBV$AMGN
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport